Welcome to our dedicated page for Envveno Medical news (Ticker: NVNO), a resource for investors and traders seeking the latest updates and insights on Envveno Medical stock.
enVVeno Medical Corporation develops bioprosthetic venous valve devices for severe deep chronic venous insufficiency in the United States. News about NVNO centers on the company’s enVVe System, a minimally invasive transcatheter replacement venous valve, and its TAVVE pivotal study under FDA investigational device exemption approval.
Recurring updates also cover the VenoValve surgical replacement venous valve, FDA communications tied to device review, clinical-development planning, cash runway and operating losses, Nasdaq listing compliance, shareholder-approved capital-structure actions such as the reverse stock split, and investor communications from this late clinical-stage medical device issuer.
enVVeno Medical announced positive interim data from the SAVVE U.S. pivotal trial for the VenoValve, presented at the Society for Vascular Surgery 2024 Annual Meeting. Of the 21 venous ulcer patients evaluated at one year, 91% have either fully healed ulcers or improved conditions. Specifically, 100% of ulcers existing for a year or less before the VenoValve surgery completely healed, and 89% of ulcers older than one year either healed or improved. Impressively, there have been no ulcer recurrences. The company plans to file for FDA approval in Q4 2024.
The SAVVE study is a prospective, non-blinded, single-arm, multi-center study involving 75 CVI patients across 21 U.S. sites. As of March 31, 2024, enVVeno had $42.9 million in cash and investments.
enVVeno Medical announced the presentation of new interim venous ulcer healing data from the VenoValve U.S. pivotal trial at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024. The data, presented by Dr. Cassius Iyad Ochoa Chaar of Yale School of Medicine, includes healing and improvement rates for venous ulcers among 21 patients reaching the one-year milestone. The study involves patients with severe venous ulcers who had undergone multiple existing treatments. The FDA requires one-year data on all SAVVE patients for the VenoValve's PMA application, expected to be filed in Q4 2024.
enVVeno Medical reported financial results for the first quarter of 2024, ending with $42.9 million in cash and investments.
Positive 11-month efficacy data was presented at the Charing Cross Symposium. The Company is on track to file for FDA approval for VenoValve in Q4 2024.
Andrew Cormack joined as Chief Commercial Officer, and progress was made in the development of the enVVe valve and delivery system.
Financially, the Company had a cash burn of $3.5 million, lower than expected, with net losses decreasing by 22% compared to the same period last year.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.